Nuclear Medicine: Page 2

EANM: Affibody presents data on HER2 radioligand therapy

By AuntMinnieEurope.com staff writers

The Stockholm, Sweden-based company is highlighting progress across its radiopharmaceutical pipeline.

October 19, 2026

EANM: Akiram presents first clinical data for CD44v6-targeted therapy

By AuntMinnieEurope.com staff writers

The first-in-human ongoing phase I trial is evaluating Lu-177 AKIR001 in patients with irresectable or metastatic CD44v6-positive solid tumors.

October 19, 2026

Nuclidium, NorthStar sign Cu-67 supply and manufacturing deal

By AuntMinnie.com staff writers

Cu-67 is the therapeutic half of Nuclidium’s theranostic platform, which pairs it with copper-61 (Cu-61) for diagnostic imaging.

October 19, 2026

From theranostics to patient access: What to expect at EANM 2026

By Claudia Tschabuschnig

Around 10,000 participants from 138 countries are expected in Vienna as nuclear medicine expands its role in cancer treatment and molecular imaging.

October 15, 2026

Lu-177 PNT2002 before SBRT extends disease control in prostate cancer

By Will Morton

A group from the University of California, Los Angeles, updated an analysis of outcomes from the LUNAR trial by 10 months.

October 13, 2026

Nuclidium images first patient in phase II trial of Cu-61 PSMA tracer

By AuntMinnieEurope.com staff writers

The trial will enroll nearly three dozen patients with biopsy-confirmed metastatic prostate cancer at U.S. sites.

October 6, 2026

Mevion to install proton therapy system in Istanbul

By AuntMinnieEurope.com staff writers

The installation will establish the first proton therapy program in Türkiye's private healthcare sector.

September 29, 2026

European Nuclear Medicine Day to tackle access gaps across Europe

By Claudia Tschabuschnig

EANM and Nuclear Medicine Europe will bring policymakers, clinicians, industry, and patients together in Brussels on 29 September to push for more equitable access to nuclear medicine across Europe.

September 25, 2026

Telix signs agreement to acquire ITM

By Erik L. Ridley

The deal would create a combined company with significant radioisotope manufacturing, distribution, and radiopharmaceutical development capabilities.

September 21, 2026

Sustainability in cancer care: from machines to systems

By Claudia Tschabuschnig

Speakers at a session at the IAEA Scientific Forum asked what remains after the machine has been installed.

September 21, 2026

IAEA Scientific Forum: Can automated planning shorten radiotherapy waits?

By Claudia Tschabuschnig

Research promising one-second treatment planning prompted discussion of workforce shortages and delays in cancer care at the IAEA Scientific Forum in Vienna.

September 17, 2026

Radiation medicine aims to tackle cancer care inequalities in low-income countries

By Claudia Tschabuschnig

Health experts discussed challenges facing cancer care in low income countries, the potential of theranostics as well as AI, covering various topics to bridge global health disparities at the IAEA Scientific Forum in Vienna.

September 16, 2026

Previous Page

Page 2 of 8

Next Page